|
2025
|
Invention
|
Methods for the treatment of angptl3-related diseases and disorders.
Described are methods for t... |
|
|
Invention
|
Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof.
The invention provid... |
|
2024
|
Invention
|
Rnai agents for inhibiting expression of activin receptor-like kinase 7 (alk7), compositions ther... |
|
|
Invention
|
Methods and reagents for improved oligonucleotide synthesis. Provided herein are improved reagent... |
|
|
Invention
|
Lipid conjugates for the delivery of therapeutic agents to cns tissue.
Disclosed herein are comp... |
|
|
Invention
|
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin.
The invention re... |
|
|
Invention
|
Subcutaneous delivery of rnai agents for inhibiting expression of receptor for advanced glycation... |
|
|
Invention
|
Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositi... |
|
|
Invention
|
Oligonucleotide synthesis methods. Disclosed herein are processes or methods for producing oligon... |
|
|
Invention
|
Rnai agents for inhibiting expression of coronavirus (cov) viral genomes, compositions thereof, a... |
|
|
Invention
|
Trialkyne linking agents and methods of use.
Described are improved linking agents that are usef... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cardiometabolic diseases. |
|
|
Invention
|
Rnai agents for inhibiting expression of pnpla3, pharmaceutical compositions thereof, and methods... |
|
|
Invention
|
Compositions and methods for inhibiting gene expression of lpa.
RNA interference (RNAi) agents a... |
|
|
Invention
|
Hepatic delivery platforms for multimeric rnai agent conjugates and methods of use thereof. in vi... |
|
|
Invention
|
Metabolically stabilized carbohydrate targeting ligands for oligonucleotide conjugates. in vivoin... |
|
|
Invention
|
Rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions t... |
|
|
Invention
|
Rnai agents for inhibiting expression of complement factor b (cfb) pharmaceutical compositions th... |
|
|
Invention
|
Rnai agents for inhibiting expression of ataxin-2 (atxn2), compositions thereof, and methods of u... |
|
|
Invention
|
Rnai agents for inhibiting expression of mitochondrial amidoxime reducing component 1 (marc1), ph... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of
cardiometabolic diseases. |
|
|
Invention
|
Rnai agents for inhibiting expression of pcsk9, pharmaceutical compositions thereof, and methods ... |
|
|
Invention
|
Rnai agents for inhibiting expression of thymic stromal lymphopoietin (tslp), compositions thereo... |
|
|
Invention
|
Optimized rnai agents for inhibiting expression of coronavirus (cov) viral genomes, compositions ... |
|
|
Invention
|
Belt reactor manufacturing process for oligomer synthesis. A method and apparatus for synthesis o... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cardiometabolic diseases |
|
|
Invention
|
Rnai agents for inhibiting influenza a viral gene expression, compositions thereof, and methods o... |
|
|
Invention
|
Lipid conjugates for the delivery of therapeutic agents to adipose tissue. e.gin vivo in vivo in ... |
|
2023
|
Invention
|
Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use... |
|
|
Invention
|
Rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical composition... |
|
|
Invention
|
Rnai agents for inhibiting expression of dm1 protein kinase (dmpk) compositions thereof, and meth... |
|
|
Invention
|
Methods for the treatment of angptl3-related diseases and disorders. Described are methods for tr... |
|
|
Invention
|
Methods for the treatment of angptl3-related diseases and disorders |
|
|
Invention
|
Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and... |
|
|
Invention
|
Lipid conjugates for the delivery of therapeutic agents to cns tissue |
|
|
Invention
|
Lipid conjugates for the delivery of therapeutic agents to cns tissue. in vivoin vivo. The PK/PD ... |
|
|
Invention
|
Treatment of a non-alcoholic fatty liver disease. Described are methods of treatment of a non-alc... |
|
|
Invention
|
Skeletal muscle delivery platforms and methods of use.
The present disclosure relates to deliver... |
|
|
Invention
|
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use.
Describ... |
|
|
Invention
|
Integrin targeting ligands and uses thereof.
Synthetic αvβ6 integrin ligands of Formula I having... |
|
|
Invention
|
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use. Describe... |
|
|
Invention
|
Skeletal muscle delivery platforms and methods of use thereof.
The present disclosure relates to... |
|
|
Invention
|
Integrin ligands and uses thereof.
Synthetic αvβ6 integrin ligands of Formula I having serum sta... |
|
2022
|
Invention
|
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3). The prese... |
|
|
Invention
|
Rnai therapy for hepatitis b virus infection.
Described are compositions and methods for inhibit... |
|
|
Invention
|
Rnai agents for hepatitis b virus infection.
Described are compositions and methods for inhibiti... |
|
2021
|
Invention
|
Methods for the reduction of z-aat protein levels.
Described are methods of reducing liver Z-AAT... |
|
2018
|
P/S
|
Pharmaceutical and medicinal preparations to treat cancer, hepatitis, cardiovascular disease, lun... |
|
|
P/S
|
Pharmaceutical and medicinal preparations to treat
intractable diseases in humans. Development o... |
|
2016
|
P/S
|
Development of pharmaceutical preparations and medicines; Pharmaceutical products development; Ph... |
|
|
P/S
|
Pharmaceutical and medicinal preparations to treat intractable diseases in humans |
